Tsao covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, RVL Pharmaceuticals, and Roivant Sciences. According to TipRanks, Tsao has an average return of 1.2% and a 38.29% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $10.33 average price target.
SCPH market cap is currently $178.7M and has a P/E ratio of -5.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Read More on SCPH:
- scPharmaceuticals announces data presentations at HFSA annual meeting
- scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
- scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update